PMID- 31037994
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20200921
IS  - 1369-1635 (Electronic)
IS  - 0953-7104 (Linking)
VI  - 31
IP  - 3
DP  - 2020
TI  - Influence of rabeprazole and famotidine on pharmacodynamic profile of dual 
      antiplatelet therapy in clopidogrel-sensitive patients: The randomized, 
      prospective, PROTECT trial.
PG  - 329-336
LID - 10.1080/09537104.2019.1609667 [doi]
AB  - Although acid suppressants are needed to attenuate gastrointestinal bleeding 
      (GIB) after percutaneous coronary intervention (PCI), pharmacodynamic interaction 
      between clopidogrel and proton pump inhibitor (PPI) can increase the risk of high 
      platelet reactivity (HPR). We sought to evaluate serial changes of platelet 
      measures and influence of rabeprazole on platelet measures. After 600-mg 
      clopidogrel loading for elective PCI, clopidogrel-sensitive patients were 
      recruited and randomly assigned to add rabeprazole of daily 20 mg (n = 40) or 
      famotidine of daily 40 mg (n = 40). Platelet measures were performed with light 
      transmittance aggregometry and VASP-P assay. Primary endpoint was 5 muM 
      ADP-induced platelet aggregation (PA) at 30-day follow-up. HPR was defined as 5 
      muM ADP-induced PA > 46%. Baseline platelet measures did not differ significantly 
      between the groups. The 30-day level of 5 muM ADP-induced PA was similar between 
      the famotidine vs. rabeprazole group (30.0 +/- 16.4% vs. 30.2 +/- 13.9%, P= .956). In 
      addition, other platelet measures were comparable between the groups. At 30-day 
      follow-up, the incidence of HPR was similar between the famotidine and 
      rabeprazole groups (20.5% vs. 15.4%; P= .555). In conclusion, adjunctive use of 
      rabeprazole showed the similar antiplatelet effect even in clopidogrel-sensitive 
      patients compared with adjunctive famotidine, which may support the similar 
      effect of rabeprazole and famotidine on the antiplatelet effect of dual 
      antiplatelet therapy with clopidogrel plus aspirin.
FAU - Ahn, Jong-Hwa
AU  - Ahn JH
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Cardiovascular Center, Gyeongsang National University Changwon 
      Hospital, Changwon, South Korea.
FAU - Park, Yongwhi
AU  - Park Y
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Cardiovascular Center, Gyeongsang National University Changwon 
      Hospital, Changwon, South Korea.
FAU - Bae, Jae Seok
AU  - Bae JS
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Cardiovascular Center, Gyeongsang National University Changwon 
      Hospital, Changwon, South Korea.
FAU - Jang, Jeong Yoon
AU  - Jang JY
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Cardiovascular Center, Gyeongsang National University Changwon 
      Hospital, Changwon, South Korea.
FAU - Kim, Kye-Hwan
AU  - Kim KH
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Gyeongsang National University Hospital, Jinju, South Korea.
FAU - Kang, Min Gyu
AU  - Kang MG
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Gyeongsang National University Hospital, Jinju, South Korea.
FAU - Koh, Jin-Sin
AU  - Koh JS
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Gyeongsang National University Hospital, Jinju, South Korea.
FAU - Park, Jeong Rang
AU  - Park JR
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Gyeongsang National University Hospital, Jinju, South Korea.
FAU - Hwang, Seok-Jae
AU  - Hwang SJ
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Gyeongsang National University Hospital, Jinju, South Korea.
FAU - Kwak, Choong Hwan
AU  - Kwak CH
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Cardiovascular Center, Gyeongsang National University Changwon 
      Hospital, Changwon, South Korea.
FAU - Hwang, Jin-Yong
AU  - Hwang JY
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Gyeongsang National University Hospital, Jinju, South Korea.
FAU - Jeong, Young-Hoon
AU  - Jeong YH
AD  - Department of Internal Medicine, Gyeongsang National University School of 
      Medicine and Cardiovascular Center, Gyeongsang National University Changwon 
      Hospital, Changwon, South Korea.
AD  - Institute of the Health Sciences, Gyeongsang National University, Jinju, South 
      Korea.
LA  - eng
PT  - Journal Article
DEP - 20190430
PL  - England
TA  - Platelets
JT  - Platelets
JID - 9208117
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
RN  - 5QZO15J2Z8 (Famotidine)
RN  - A74586SNO7 (Clopidogrel)
SB  - IM
MH  - Aged
MH  - Clopidogrel/adverse effects/*pharmacokinetics
MH  - Drug Interactions
MH  - Famotidine/administration & dosage/adverse effects/*pharmacology
MH  - Female
MH  - Gastrointestinal Hemorrhage/diagnosis/drug therapy/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/*pharmacokinetics
MH  - Platelet Function Tests
MH  - Proton Pump Inhibitors/administration & dosage/adverse effects/*pharmacology
MH  - Rabeprazole/administration & dosage/adverse effects/*pharmacology
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Clopidogrel
OT  - GI bleeding
OT  - famoditine
OT  - rabeprazole
EDAT- 2019/05/01 06:00
MHDA- 2020/09/22 06:00
CRDT- 2019/05/01 06:00
PHST- 2019/05/01 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
PHST- 2019/05/01 06:00 [entrez]
AID - 10.1080/09537104.2019.1609667 [doi]
PST - ppublish
SO  - Platelets. 2020;31(3):329-336. doi: 10.1080/09537104.2019.1609667. Epub 2019 Apr 
      30.